MAPS
MAPS · page 2
- Markets & Stocks
Cannabis Stocks Today — Tuesday 12 May 2026: Cronos Trades at $2.75 as Ayr Wellness Slips Toward $0.01
Cannabis equities head into Tuesday’s pre-market session with the sector broadly divided, following a Monday close in which upward and downward pressure across the tracked universe roughly offset one another.
- Markets & Stocks
Cannabis Stocks Today — Friday 8 May 2026: Mixed Session as WM Technology Gains 14%
BoC Cannabis Index closes +0.61% but breadth turns negative as 23 of 38 names fall; WM Technology surges 14% while REFI leads losers down 5%.
- Markets & Stocks
Cannabis Stocks Today — Thursday 7 May 2026: Curaleaf Leads +9.4% as Sector Rallies
BoC Cannabis Index +1.67% on broad strength; Curaleaf +9.4% leads a 27-stock advance, IIPR -4.3% the day’s worst.
- Markets & Stocks
Cannabis Stocks Today — Wednesday 6 May 2026: Innovative Industrial Properties Leads +14.03% as Sector Rallies
BoC Cannabis Index gains +1.26% as Innovative Industrial Properties surges +14.03%, lifting US MSOs and ETFs in a synchronised cannabis rally.
- Markets & Stocks
Cannabis Stocks Today — Thursday 30 April 2026: Ayr Wellness Leads +30.7% as Sector Rallies
Cannabis stocks closed broadly higher Thursday with the BoC Cannabis Index up 2.65%, every ETF gaining at least 3.9%, and Ayr Wellness pacing the universe at +30.7% even as several US MSOs lagged the rally.
- Markets & Stocks
Cannabis Stocks Today — Wednesday 29 April 2026: Sector Slides as MAPS Falls 12.9%
The BoC Cannabis Index fell roughly 3.3% on Wednesday with 32 of 39 tracked stocks closing lower; Trulieve led gainers (+7.0%) while WM Technology slumped 12.9%.
- Markets & Stocks
Cannabis Stocks Today — Tuesday 28 April 2026: Cresco Labs Leads +19% as US MSOs Rally
BoC Cannabis Index edges +0.34% as US multi-state operators rally led by Cresco Labs +19%, while cannabis ETFs and Canadian LPs slide.
- Uncategorized
FDA Approves Clinical Trial Into Cannabis as a Treatment for PTSD Following a 3-Year Block
The US Food and Drug Administration (FDA) has finally approved a Phase 2 clinical trial into cannabis in treatment of post-traumatic stress disorder (PTSD), three years after being put on hold.
